Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 954.00 | |
50 mg | 8-10 weeks | $ 1,240.00 | |
100 mg | 8-10 weeks | $ 1,990.00 |
Description | Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections. |
In vitro | Avarofloxacin demonstrates an antibacterial effect against numerous Gram-positive bacteria (mean MIC90: 0.12 mg/L) [2]. Avarofloxacin has the potential for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections [3]. |
Synonyms | JNJ-Q2 |
Molecular Weight | 419.42 |
Formula | C21H23F2N3O4 |
CAS No. | 878592-87-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Avarofloxacin 878592-87-1 Others JNJ-Q2 inhibitor inhibit